Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies
Exploration of Immunology · 07.06.2022 · 334-350
DOI: 10.37349/ei.2022.00054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Exploration of Immunology, online erschienen am 07.06.2022. Verfasst von Navdeep Jhita und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University …. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Cancer immunotherapy, especially T-cell driven targeting, has significantly evolved and improved over the past decade, paving the way to treat previously refractory cancers. Hematologic malignancies, given their direct tumor accessibility and less immunosuppressive microenvironment compared to solid tumors, are better suited to be targeted by cellular immunotherapies. Gamma delta (γδ) T cells, with their unique attributes spanning the entirety of the immune system, make a tantalizing therapeutic platform for cancer immunotherapy. Their inherent anti-tumor properties, ability to act like antigen-presenting cells, and the advantage of having no major histocompatibility complex (MHC) restrictions, allow for greater flexibility in their utility to target tumors, compared to their αβ T cell counterpart. Their MHC-independent anti-tumor activity, coupled with their ability to be easily expanded from peripheral blood, enhance their potential to be used as an allogeneic product. In this review, the potential of utilizing γδ T cells to target hematologic malignancies is described, with a specific focus on their applicability as an allogeneic adoptive cellular therapy product.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cell and Gene Therapy Program, Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA 30322, USA.
ORCID-Profile: Navdeep Jhita, Sunil S Raikar
Förderung
- NCI NIH HHS
Zitieren
APA
Jhita, N., & Raikar, S. S. (2022). Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies. Exploration of Immunology, 334-350. https://doi.org/10.37349/ei.2022.00054
Vancouver
Jhita N, Raikar SS. Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies. Exploration of Immunology. 2022:334-350. doi:10.37349/ei.2022.00054
BibTeX
@article{Jhita2022,
author = {Jhita, Navdeep and Raikar, Sunil S},
title = {Allogeneic gamma delta T cells as adoptive cellular therapy for hematologic malignancies},
journal = {Exploration of Immunology},
year = {2022},
pages = {334--350},
doi = {10.37349/ei.2022.00054}
}
EUVIMED